

Table 2: Output restriction cases (end 2018 to Q1 2025)

Case	Participants	Restriction conducts	Restriction methods
Norepinephrine API and epinephrine API case (Grandpharma and Wuhan Huihai) (2023) ²²	The only two nationwide producers of relevant APIs	Sales restriction	The two companies agreed that Wuhan Huihai would stop supplying the APIs, with Grandpharma providing compensation.
Fluorouracil injection case (Shanghai Xudong and Tianjin Tianyao) (2023)	The two major nationwide fluorouracil injection producers	Sales restriction	The companies coordinated to limit sales quotas, reducing supply in designated market areas.

Read the full legal update:

[Pharmaceutical sector in focus: Decoding recent antitrust enforcement – Part 2 of 3](#)